Dec. 18, 2024 — Until now, scientists have been unable to determine how metformin, a Type 2 diabetes medication that lowers blood sugar, works. A study provided direct evidence in mice that it ...

Clearmind Medicine (CMND) announces advancement in its proprietary MEAI- based binge behavior regulator program through the granting of patent ...

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to ...

DALLAS, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Berry Corporation (bry) (NASDAQ: BRY) ("Berry” or the "Company”) announced the closing of a comprehensive refinancing of its existing indebtedness on December ...

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development ...

On Tuesday, Clearmind Medicine Inc (CMND) stock saw a modest uptick, ending the day at $1.72 which represents a slight increase of $0.50 or 40.98% from the prior close of $1.22. The stock opened at $2 ...

Prostate cancer hijacks the normal prostate's growth regulation program to release the brakes and grow freely, according to Weill Cornell Medicine researchers. Transportation noise poses serious ...

Clearmind Medicine's stock rose 63.9% after receiving IRB approval for its Phase I/IIa trial of CMND-100, a drug for alcohol ...

Shares of Clearmind Medicine more than doubled after the Institutional Review Board approved a clinical trial of its flagship compound as a treatment for alcohol use disorder. The stock was changing ...

US stock futures are treading water in Tuesday's premarket session ahead of a shortened trading day before the markets close for Christmas on Wednesday. The Dow Jones Industrial Average futures were ...

Clearmind Medicine (CMND) announced it has received Institutional Review Board approval for its Phase I/IIa clinical trial of CMND-100, ...

Vancouver, Canada, Dec. 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel ...